Search - tctmd.com

Displaying 21 - 40 of 40

Sort: Relevancy | Date

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

August 31, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.